Jim Jasper

African-Americans are more likely to develop lupus than Caucasians, but less likely to take part in clinical trials of the disease. However, a new study showed that several simple steps, such as providing transportation and flexible scheduling, may allow more African-Americans to participate in trials. The study was conducted by top lupus experts including Dr. … New Study Presents Strategies That Helped African-Americans Take Part In Lupus Trials

New research published in Arthritis and Rheumatology shows that peripheral nervous system (PNS) disease is an important part of neuropsychiatric lupus with significant effects on quality of life.  The peripheral nervous system is the network that sends signals between the brain and spinal cord (the central nervous system) with all the other parts of the … Lupus Has Nerve Shows Large International Study

The Lupus Research Alliance (LRA) is pleased to share that a potential new treatment in development by Equillium, Inc. for lupus nephritis, itolizumab, was granted Fast Track designation by the U.S. Food and Drug Administration.  As defined by the FDA, this designation is “designed to facilitate the development, and expedite the review of drugs to … Great News for Lupus Nephritis Treatment: Itolizumab Fast-Tracked by FDA

The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly encouraged by the positive results reported for several potential new treatments that may help people with lupus. “The foundational work the Lupus Research Alliance and others have supported is beginning to bear fruit with potential therapies like anifrolumab, … Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments

The Lupus Research Alliance is excited to announce that a potential new medicine for lupus—anifrolumab—reduced disease activity versus placebo in a second Phase III study. Anifrolumab is a therapeutic antibody that blocks type I interferons, a molecule that promotes lupus inflammation. The LRA was ahead of the curve by funding more than 15 studies that … Potential New Treatment in Phase III Trial

The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel J. Wallace, MD joins as a new member of its distinguished Board of Directors. A renowned leader in clinical research and care for lupus and other rheumatologic diseases, Dr. Wallace is Medical Director of the Wallace Rheumatic Study Center and Associate … Welcoming Daniel J. Wallace, MD to Lupus Therapeutics

Many dynamics of lupus contribute to the fact that its complexities have eluded the scientific community—but new hope may come from patients themselves. This is why Lupus Therapeutics piloted the Patient Advocates for Lupus Studies (PALS) program in the Summer of 2019. PALS focuses on reaching diverse populations to improve their knowledge and awareness of … Peer-to-Peer Involvement Advances Scientific Exploration

The Lupus Research Alliance (LRA)—going bold and thinking big—has once again shifted the status quo of lupus research by becoming the first and only lupus organization to conduct its own clinical trials. How did we achieve what once seemed unobtainable? We created Lupus Therapeutics (an LRA affiliated organization) and since the program started in 2017, … Lupus Therapeutics Shifting the Paradigm

TAK-079A Study to Evaluate the Safety of TAK-079 PAISLEY-SLEA Phase II study to evaluate a novel, oral therapy in SLE ORKIDSA study to evaluate the effects of krill oil in SLE LOTUSA Phase III study to evaluate Stelara® in SLE DIVINEA study to evaluate a novel imaging procedure to access Lupus Nephritis (LN) RIFLEA study … 10 Lupus Therapeutics Studies Currently Underway